Ovid crashes out in Angelman syndrome
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
The promise and the perils of antigen testing
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
Glaxo moves up a place in the RSV treatment race
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Interest in Tyk2 might soon tick up
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
Aducanumab: this time it’s personal
The focus shifts to whether the FDA will overrule its own panel and approve the Alzheimer’s project.
Anti-amyloid approaches come back from the dead
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
